Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies - PubMed (original) (raw)
Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies
Yoshiaki Nishimura et al. J Virol. 2002 Mar.
Abstract
We previously reported that high-titered neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope can block the establishment of a simian immunodeficiency virus (SIV)/HIV chimeric virus (SHIV) infection in two monkeys following passive transfer (R. Shibata et al., Nat. Med. 5:204-210, 1999). In the present study, increasing amounts of neutralizing immunoglobulin G (IgG) were administered to 15 pig-tailed macaques in order to obtain a statistically valid protective neutralization endpoint titer in plasma. Using an in vitro assay which measures complete neutralization of the challenge SHIV, we correlated the titers of neutralizing antibodies in plasma at the time of virus inoculation (which ranged from 1:3 to 1:123) with the establishment of infection in virus-challenged animals. Ten of 15 monkeys in the present experiment were virus free as a result of neutralizing IgG administration as monitored by DNA PCR (peripheral blood mononuclear cells and lymph node cells), RNA PCR (plasma), virus isolation, and the transfer of lymph node cell suspensions (10(8) cells) plus 8 ml of whole blood from protected animals to naïve macaques. The titer of neutralizing antibodies in the plasma calculated to protect 99% of virus-challenged monkeys was 1:38.
Figures
FIG. 1.
Endpoint titrations of anti-SHIVDH12 neutralizing activities present in purified chimpanzee IgGs. The virus-neutralizing activities in IgGs purified from a chimpanzee chronically infected with HIV-1DH12 (top) or a virus-naïve animal (bottom) were evaluated in quadruplicate cultures of MT-4 cells following a 1-h incubation of virus (75 TCID50) with threefold serial dilutions of plasma. The presence or absence of progeny virus production was measured by 32P-reverse transcriptase assays performed on aliquots of the culture supernatant from day 14 of infection. The black spots shown in the autoradiograms indicate the presence of virion-associated reverse transcriptase activity (i.e., no virus neutralization).
FIG. 2.
Neutralization titers in plasma following the passive transfer of large amounts of purified chimpanzee IgG to naïve pig-tailed macaques. Shown are endpoint neutralization titers in pairs of monkeys receiving the maximum amounts of IgG from an HIV-1-infected (left panels) or naïve (right panels) chimpanzee. The neutralization assays were performed with samples collected immediately prior to IgG administration (day −1) and SHIVDH12 challenge (day 0). Assays were carried out as described in the legend to Fig. 1.
FIG. 3.
PBMC-associated viral DNA loads in passively immunized pig-tailed macaques challenged with SHIVDH12. (A to G) DNA was prepared from PBMC, collected from recipients of anti-HIV-1DH12 IgG, and analyzed by quantitative DNA PCR over a 4-month period for the presence of SHIVDH12. (H) Levels of PBMC-associated viral DNA in the five immunized and two naïve monkeys which became infected are shown in an expanded time scale.
FIG. 4.
Plasma viral RNA levels in passively immunized pig-tailed macaques challenged with SHIVDH12. The number of SHIVDH12 RNA copies in IgG recipients was determined over a 4-month period following an intravenous SHIVDH12 challenge by quantitative RT-PCR.
Similar articles
- Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR. Parren PW, et al. J Virol. 2001 Sep;75(17):8340-7. doi: 10.1128/jvi.75.17.8340-8347.2001. J Virol. 2001. PMID: 11483779 Free PMC article. - Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B, Sok D, Schmidt SD, Abbink P, Newman RM, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen TM, Mascola JR, Burton DR, Barouch DH. Julg B, et al. J Virol. 2017 Sep 27;91(20):e01187-17. doi: 10.1128/JVI.01187-17. Print 2017 Oct 15. J Virol. 2017. PMID: 28768869 Free PMC article. - Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA. Shibata R, et al. Nat Med. 1999 Feb;5(2):204-10. doi: 10.1038/5568. Nat Med. 1999. PMID: 9930869 - Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, Vlasak J, Xu W, Baba TW, Chenine AL, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Montefiori DC, McClure HM. Ruprecht RM, et al. Transfus Clin Biol. 2001 Aug;8(4):350-8. doi: 10.1016/s1246-7820(01)00187-2. Transfus Clin Biol. 2001. PMID: 11642027 Review. - Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.
Xu W, Hofmann-Lehmann R, McClure HM, Ruprecht RM. Xu W, et al. Vaccine. 2002 May 6;20(15):1956-60. doi: 10.1016/s0264-410x(02)00077-4. Vaccine. 2002. PMID: 11983253 Review.
Cited by
- Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice.
Karaaslan E, Sorvillo TE, Scholte FEM, O'Neal TJ, Welch SR, Davies KA, Coleman-McCray JD, Harmon JR, Ritter JM, Pegan SD, Montgomery JM, Spengler JR, Spiropoulou CF, Bergeron É. Karaaslan E, et al. NPJ Vaccines. 2024 Aug 14;9(1):148. doi: 10.1038/s41541-024-00931-y. NPJ Vaccines. 2024. PMID: 39143104 Free PMC article. - Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli.
Araujo SC, Pereira LR, Alves RPS, Andreata-Santos R, Kanno AI, Ferreira LCS, Gonçalves VM. Araujo SC, et al. Vaccines (Basel). 2020 Aug 31;8(3):492. doi: 10.3390/vaccines8030492. Vaccines (Basel). 2020. PMID: 32878023 Free PMC article. Review. - Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent d-peptide HIV entry inhibitor.
Nishimura Y, Francis JN, Donau OK, Jesteadt E, Sadjadpour R, Smith AR, Seaman MS, Welch BD, Martin MA, Kay MS. Nishimura Y, et al. Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22436-22442. doi: 10.1073/pnas.2009700117. Epub 2020 Aug 20. Proc Natl Acad Sci U S A. 2020. PMID: 32820072 Free PMC article. - Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
Caskey M, Klein F, Nussenzweig MC. Caskey M, et al. Nat Med. 2019 Apr;25(4):547-553. doi: 10.1038/s41591-019-0412-8. Epub 2019 Apr 1. Nat Med. 2019. PMID: 30936546 Free PMC article. Review. - Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, Vignaud A, Collaud F, Charles S, Simon Sola M, Jouen F, Boyer O, Mingozzi F. Fitzpatrick Z, et al. Mol Ther Methods Clin Dev. 2018 Feb 13;9:119-129. doi: 10.1016/j.omtm.2018.02.003. eCollection 2018 Jun 15. Mol Ther Methods Clin Dev. 2018. PMID: 29766022 Free PMC article.
References
- American Academy of Pediatrics. 1997. Report of the Committee on Infectious Diseases, 24th ed. American Academy of Pediatrics, Elk Grove Village, Ill.
- Brander, C., and B. D. Walker. 1999. T lymphocyte responses in HIV-1 infection: implications for vaccine development. Curr. Opin. Immunol. 11:451-459. - PubMed
- Cho, M. W., Y. B. Kim, M. K. Lee, K. C. Gupta, W. Ross, R. Plishka, A. Buckler-White, T. Igarashi, T. Theodore, R. Byrum, C. Kemp, D. C. Montefiori, and M. A. Martin. 2001. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75:2224-2234. - PMC - PubMed
- Committee on Care and Use of Laboratory Animals. 1985. Guide for the care and use of laboratory animals. NIH 85-23. Department of Health and Human Services, Washington, D.C.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical